Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00989313 · ClinicalTrials.gov registry record
A Long Term Follow up Study of Patients Who Have Complete Clearance of Their Actinic Keratosis (AK) Lesions at the Day 57 Visit in the PEP005-028 Study
A clinical trial, sponsored by Peplin.
- Completed
- Registry status
- 43
- Enrollment target
NCT00989313: Completed study, sponsored by Peplin.
NCT00989313 is a clinical trial that has completed, run by Peplin. The registered enrollment target is 43 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00989313 has completed, sponsored by Peplin.
- COMPLETED
- Registry status
- 43 participants
- Enrollment target
Study Summary
This study is designed to follow up patients, who have participated in the PEP005-028 study and observed complete clearance of their Actinic Keratosis (AK) lesions, over a 12 month period to assess both recurrence of AK lesions and long term safety in the selected treatment area.
Interventions
- DRUG Lesion count
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2009-09 |
| Est. Completion | 2010-10 |
What the finished NCT00989313 record still lists
NCT00989313 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 43 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Lesion count is the first listed.
NCT00989313 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00989313 about?
NCT00989313 is a clinical study titled "A Long Term Follow up Study of Patients Who Have Complete Clearance of Their Actinic Keratosis (AK) Lesions at the Day 57 Visit in the PEP005-028 Study". This study is designed to follow up patients, who have participated in the PEP005-028 study and observed complete clearance of their Actinic Keratosis (AK) lesions, over a 12 month period to assess both recurrence of AK lesions and long term safety in the selected treatment area.
What is the current status of trial NCT00989313?
This trial is currently completed. The enrollment target is 43 participants. The study started on 2009-09. Estimated completion is 2010-10.
What interventions are being tested in trial NCT00989313?
The interventions under investigation include: Lesion count (DRUG).
Who is sponsoring clinical trial NCT00989313?
This trial is sponsored by Peplin, which has 19 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03726359 · 43 participants · Phase 1
Phase I Study of Fractionated Stereotactic Radiation Therapy
- NCT03850418 · 43 participants · Phase 2
Azacitidine and Chimerism in MDS or AML Patients After Allogeneic Stem Cell Transplant
- NCT04144023 · 43 participants · Phase 1
A Vaccine (H2NVAC) Before Surgery for the Treatment of HER2-Expressing Ductal Carcinoma In Situ
- NCT04176718 · 43 participants · Phase 2
Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia